CoreMap exists to improve patient outcomes by delivering advanced diagnostic technology to electrophysiologists and patients. Our technologies will allow for patient specific treatments, because when treating the 24M patients with permanent and persistent AF 'one size does not fit all'.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/17/20 | $10,500,000 | Series A |
Fifth Focus HRMG Investments North Point Partners OrbiMed Advisors Qure Ventures  Ronny Ginor The Fund at Hula University of Vermont Ventures | undisclosed |
